Regeneron Pharmaceuticals (REGN) shares were down over 2% in recent Friday trading after multiple media reports said that a US appeals court denied the company's request to block sales of biosimilar versions of its drug Eylea.
The company was seeking to prevent Amgen (AMGN) and others from marketing copy-cat versions of its treatment for wet macular degeneration but the US Court of Appeals for the Federal Circuit upheld an earlier decision to deny Regeneron's motion for patent infringement.
The earlier motion was denied on grounds that the company could not prove Amgen infringed on Regeneron's patents covering a vial containing Eylea, according to reports.
Price: 664.59, Change: -16.02, Percent Change: -2.35
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。